Jak inhibition, but not Stat1 knockdown, blocks the synergistic effect of IFN-γ on Fas-induced apoptosis of A549 human non-small cell lung cancer cells

Journal of Interferon and Cytokine Research

Volumn 27, Issue 1, 2007, Pages 23-31

  Kurdi, Mazen ^a   Booz, George W ^a,b  

^a TEXAS A AND M UNIVERSITY SYSTEM   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FAS ANTIGEN; GAMMA INTERFERON; JANUS KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; JANUS KINASES; LUNG NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 33846597975     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0074     Document Type: Article

References (22)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics 2005. CA Cancer J. Clin. 2005;55:10-30.
2. Mountain CF. The international system for staging lung cancer. Semin. Surg. Oncol. 2000;18:106-115.
3. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J. Cancer 2003;103:153-160.
4. Tiseo M, Franciosi V, Grossi F, Ardizzoni A. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? Eur. J. Cancer 2006;42:8-16.
5. Stephanou A, Latchman DS. Opposing actions of Stat-1 and Stat-3. Growth Factors 2005;23:177-182.
6. Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2005;2:315-324.
7. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-4165.
8. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003;63:1270-1279.
9. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin. Cancer Res. 2005;11:8288-8294.
10. Coulter KR, Doseff A, Sweeney P, Wang Y, Marsh CB, Wewers MD, Knoell DL. Opposing effect by cytokines on Fas-mediated apoptosis in A549 lung epithelial cells. Am. J. Respir. Cell Mol. Biol. 2002;26:58-66.
11. Kim KB, Choi YH, Kim IK, Chung CW, Kim BJ, Park YM, Jung YK. Potentiation of Fas- and TRAIL-mediated apoptosis by IFN-gamma in A549 lung epithelial cells: enhancement of caspase-8 expression through IFN-response element. Cytokine 2002;20:283-288.
12. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol. 2002;23:96-101.
13. Antonyak MA, Singh US, Lee DA, Boehm JE, Combs C, Zgola MM, Page RL, Cerione RA. Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. J. Biol. Chem. 2001;276:33582-33587.
14. de la Maza LM, Peterson EM, Burton LE, Gray PW, Rinderknecht E, Czarniecki CW. The antichlamydial, antiviral, and antiproliferative activities of human gamma interferon are dependent on the integrity of the C terminus of the interferon molecule. Infect. Immun. 1987;55:2727-2733.
15. Yokota S, Okabayashi T, Yokosawa N, Fujii N. Growth arrest of epithelial cells during measles virus infection is caused by upregulation of interferon regulatory factor 1. J. Virol. 2004;78:4591-4598.
16. +. FEBS J. 2005;272:4576-4589.
17. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive Stat 3 activation in malignant human lung epithelial cells. Int. J. Cancer 1999;83:564-570.
18. Platanias LC. Mechanisms of type-I and type-II interferon-mediated signaling. Nat. Rev. Immunol. 2005;5:375-386.
19. Ramana CV, Kumar A, Enelow R. Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem. Biophys. Res. Commun. 2005;327:727-733.
20. Qing Y, Stark GR. Alternative activation of Stat1 and Stat3 in response to interferon-γ. J. Biol. Chem. 2004;279:41679-41685.
21. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E. Interferon-γ induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, Stat-3 activation, and modulation by other cytokines. J. Biol. Chem. 2000;275:22895-22904.
22. Houston A, O'Connell J. The Fas signaling pathway and its role in the pathogenesis of cancer. Curr. Opin. Pharmacol. 2004;4:321-326.